Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 17/20 | 0.47 |
| ▸ | HTR2C | P28335 | 17/20 | 0.47 |
| ▸ | HTR2B | P41595 | 17/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21762803 | 1.00 | HTR2A (0.47) | HTR2AHTR2CHTR2BCHRNA7HTR3A | |
| SCHEMBL21762783 | 0.92 | HTR2A (0.45) | HTR2AHTR2CHTR2B | |
| SCHEMBL21745067 | 0.90 | HTR2A (0.44) | HTR2AHTR2CHTR2B | |
| SCHEMBL21745496 | 0.90 | HTR2A (0.44) | HTR2AHTR2CHTR2B | |
| SCHEMBL21745068 | 0.90 | HTR2A (0.44) | HTR2AHTR2CHTR2B | |
| SCHEMBL21745502 | 0.82 | HTR2A (0.38) | HTR2AHTR2CHTR2B | |
| SCHEMBL21745501 | 0.82 | HTR2A (0.38) | HTR2AHTR2CHTR2B | |
| SCHEMBL21745108 | 0.82 | HTR2A (0.38) | HTR2AHTR2CHTR2B | |
| SCHEMBL21713741 | 0.69 | HTR2A (0.45) | HTR2AHTR2CHTR2BCHRNA7HTR3A | |
| SCHEMBL21745092 | 0.69 | HTR2A (0.45) | HTR2AHTR2CHTR2BCHRNA7HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3833662-B1 | INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-17 | — | — | EP | disclosed |
| WO-2020041169-A2 | INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-27 | — | — | WO | disclosed |